Connect with us

Health

Ontario reports 170 COVID cases, lowest since September – Timmins Times

Published

 on


About 78% of Ontarians have had at least 1 COVID-19 vaccination, 44% fully vaccinated

Article content

Ontario reported 170 cases of COVID-19 on Monday, the lowest new case count in nearly 10 months. There was one new death.

Article content

Waterloo Region reported 34 new cases, Toronto 27, Grey Bruce 18 and the Haliburton, Kawartha, Pine Ridge District Health Unit reported 13 cases.

The daily case count was the lowest in Ontario since the 170 cases reported on Sept. 10 and 149 cases on Sept. 9.

The current rate is now slightly higher than the number of new cases reported in Ontario in July and August of 2020, when most days the count was between 75 and 150 new cases a day.

The province completed 12,900 COVID-19 tests  and as of 8 p.m. Sunday, some 144,795 doses of vaccines had been administered. Ontario has now administered more than 15.7 million vaccinations.

There are 155 patients in hospital, 228 in intensive care and 157 on ventilators.

Ontario has had 545,973 total cases of COVID-19, of which 534,791 are considered resolved. There have been 9,215 deaths.

Closer to home, there are no active cases and no hospitalizations. There were 400 confirmed COVID cases in Algoma District and six deaths.

The province opened up its vaccine booking portal on Monday to allow accelerated appointments for youth aged 12 to 17 to receive the Pfizer-BioNTech vaccine. Though some complained on Twitter of difficulty booking their shot, Vaccine Hunters Canada tweeted there were still many appointment times available.

About 78 per cent of Ontarians have had at least one COVID-19 vaccination and 44 per cent are fully vaccinated.

Ontario moved into Step 2 of its reopening plan last Wednesday, which allowed for larger outdoor gatherings and the opening of personal care services like hair salons, among other things.

Article content

Premier Doug Ford said the government would follow the advice of its Chief Medical Officer of Health, Dr. Kieran Moore.

“They’re the experts,” Ford said. “We’re going to work day in and day out, No. 1 to get every single business open in this province, get them back on their feet. But we’re going to do it cautiously too. We’ll take directions from the health team.”

Last week, at his first briefing in his new job, Moore urged caution in the face of the more contagious Delta variant, which according to the Ontario COVID-19 science table currently makes up 74 per cent of new cases in the province.  Moore said it would be prudent to follow the province’s plan, which calls for waiting 21 days between each stage of reopening to gauge the public health consequences.

At the news conference Monday, Ford also said he’s committed to maintaining a wage increase brought in for personal support workers during the pandemic.

Ford says it’s a “guarantee” that his government will keep the temporary $3 an hour wage bump for the workers who staff long-term care homes and similar facilities. He did not share any further details.

A spokesperson for Ford, Alexandra Adamo, said the province recently extended the pay increase to Aug. 23. However, the “premier has said many times in the past that he’s committed to making it permanent,” Adamo said in a statement.

Meanwhile, Porter Airlines announced it would resume flights on Sept. 8, including its six daily flights from Ottawa to Toronto.

It’s been more than 18 months since the airline suspended operations because of the pandemic.

Last week the airline received more than $20 million in federal loans to help it reimburse passengers whose flights were cancelled.

Porter announced Monday that it will recall 500 employees as it begins operations. Flights to U.S destinations, including New York, Washington, Boston and Chicago, will resume Sept. 17.

Adblock test (Why?)



Source link

Continue Reading

Health

Biosimilar mRNA Vaccines, Part 1: Regulatory Revolution! – The Center for Biosimilars

Published

 on


The COVID-19 pandemic has brought a remarkable shift in how we will prevent infections and autoimmune disorders in the future. The nucleic acid vaccines, including messenger RNA (mRNA) and DNA vaccines, have been under development for decades, but there was no opportunity to test their safety and efficacy; vaccines may take years and decades to provide sufficient proof of safety and efficacy. Then came COVID-19, caused by the SARS-CoV-2 virus. Fast data collection became possible because the virus was so widespread. Even with small infection numbers (n = 150) among study populations that averaged about 30,000 to 40,000, it was clear that mRNA vaccine efficacy was surprisingly high: 95% or better. The FDA would have approved the use of the mRNA vaccine at even at 50% efficacy.

The safety of the mRNA vaccines was confirmed clearly in multiple studies across the globe. However, not all COVID-19 vaccines fared well. The third mRNA vaccine, by CureVac, failed because its developers chose not to follow the teachings of the common wisdom. mRNA vaccines work by introducing a harmless piece of the virus into the body and triggering an immune response that conditions the body to recognize and attack the true virus. Moderna and Pfizer–BioNTech vaccines use modified RNA (pseudouridine); CureVac chose not to modify the RNA, and its vaccine uses normal uridine. It produced lower levels of antibodies than the Moderna and Pfizer-BioNTech vaccines and was just 47% effective at preventing COVID-19 infection. Incidentally, the name Moderna comes from “modified RNA.”

The Chinese Sinopharm vaccine, a traditional inactivated virus vaccine, also failed. This failure brought great misery because the Chinese government had used this vaccine as a diplomacy tool, supplying billions of doses to developing countries. As of today, none of the non-mRNA COVID-19 vaccines have come close to the efficacy of the mRNA vaccines.

We have 2 mRNA vaccines approved under Emergency Use Authorization (BNT162b2, mRNA-1273/NAID), and I anticipate their full approval soon. Pfizer has filed for the modification of storage temperature, and Moderna has filed for the reduction of dose; the Pfizer dose is 30 mcg, and the Moderna dose, 100 mcg. There are now newer lipid nanoparticle (LNP) formulations that can provide better temperature stability allowing only refrigeration storage.

Incidentally, Moderna has permitted the use of its patented LNP technologies to any company. Although the challenges to overcome IP issues remain, the humanitarian considerations make these challenges manageable. The US government has proposed to remove patent exclusivity relating to the COVID-19 vaccines. This action will require EU cooperation that is yet to come. However, as a patent law practitioner, I am confident that we can make COVID-19 vaccines without any patent infringement that remains in our way. mRNA vaccines have been under development for decades, so much of the base technology is already in the public domain. Both Pfizer and Moderna have shared their clinical protocol, and that is a rare event, as these protocols cost millions to produce and billions to execute. No other vaccine developer has shared these protocols in public. The mRNA vaccine developers now have a clear understanding of the regulatory process required to approve new mRNA vaccines.

Regulatory Pathway

At the time of the enactment of the Biologics Price Competition and Innovation Act (BPCIA, 2010), there was no indication that the introduction of mRNA vaccines would create a dilemma for the FDA in deciding an appropriate regulatory pathway.

The FDA’s Center for Biologics Evaluation and Research (CBER) jurisdiction includes biological products such as prophylactic and therapeutic vaccines, whole blood and blood products, cellular products and exosomal preparations, gene therapies, tissue products, and live biotherapeutic agents. CBER also regulates selected drugs and devices used to test and manufacture our biological products. In keeping with that mission, product approval applications filed with CBER include 351(a) filings, which are for “standalone” or original products, rather than biosimilars (21 Code of Federal Regulations [CFR] 601.2). The biologics license application (BLA) is regulated under 21 CFR 600 – 680.

Many biological products are controlled by the Center for Drug Evaluation and Research (CDER), including biosimilar and interchangeable biologics. For example, in March 2020, insulin, glucagon, and human growth hormone regulated as drugs under the Food, Drug, and Cosmetic Act came into the CDER BLA program.

mRNA vaccines have a unique feature: They are manufactured chemically, not biologically, as are many other vaccines. As a result, the vaccine structure is completely known, unlike the therapeutic proteins. The variations in the secondary and tertiary structures and post-expression modifications require intensive evaluation of similarity to allow them a biosimilar status. A proposed biosimilar mRNA vaccine can provide a 100% match for a reference product sequence. Thus, mRNA vaccines are closer to generic chemical products than biological therapeutic proteins.

In my opinion, the traditional vaccines can stay within the jurisdiction of CBER, and the chemically synthesized vaccines be approved under BLA by CDER under the 351(k) filing where suitable.

Already, the FDA has issued a final guideline (February 2021) on the development of products for the treatment and prevention of COVID-19, which states:

“COVID-19 vaccine development may be accelerated based on knowledge gained from similar products manufactured with the same well-characterized platform technology, to the extent legally and scientifically permissible. Similarly, with appropriate justification, some aspects of manufacture and control may be based on the vaccine platform, and in some instances, reduce the need for product-specific data. Therefore, FDA recommends that vaccine manufacturers engage in early communications with [Office of Vaccines Research and Review] to discuss the type and extent of chemistry, manufacturing, and control information needed for development and licensure of their COVID-19 vaccine.”

This statement can be construed as pointing to the possibility of a biosimilar application filing for a licensed (BLA) product to meet all requirements of the BPCIA. If the sequence of a biosimilar mRNA vaccine matches a reference product sequence, then the need for extensive toxicology and efficacy testing can be reduced, on a case-by-case basis, depending on other factors of variation. In my earlier conversation with the FDA, I appreciated the broad encouragement I received to discuss the development plan in a Type B meeting first, where the possibilities of a modified 351(a) filing or a 351(k) filing for a biosimilar mRNA vaccine can be discussed; the 351(a) modified approach will be analogous to a 505(b)(2) new drug application under the FDC Act. I will keep my readers informed of any new indications from the FDA.

mRNA vaccines are now at the forefront of hundreds of possibilities, including preventing infections to preventing autoimmune disorders. Since the antigens focused on the design of mRNA vaccines cannot be patented, a biosimilar vaccine product may likely produce the product without any infringement issue. The testing proposal presented above will help expedite the approval of biosimilars without risking the safety and efficacy of biosimilar products.

For the first time, we have a scientific challenge to meet: how to classify mRNA vaccines as chemical drugs or as biosimilars rather than standalone biologics?

In contrast to chemically synthesized small molecular weight drugs, which have a well-defined structure and can be thoroughly characterized, biological products generally derived from living material (humans, animals, or microorganisms) are complex in structure and, thus, are usually not fully characterized. However, this last consideration does not apply to mRNA vaccines.

To promote the idea of creating a new category of products, biosimilar vaccines, I have filed a citizen petition to the FDA advising the agency on creating new guidance for this new class of biosimilar products. In my opinion, the agency will agree to many of my suggestions because the issue of structural similarity with a reference product is no longer an issue. Preclinical toxicology studies can be waived based on in vitro and situ studies, requiring only comparable antibody production in animal species. The immunogenicity—stimulation of immune response—is not a significant issue because vaccines are supposed to be antigenic. A limited trial in animal species capable of showing antibody response that is comparable to findings with the reference mRNA vaccine will suffice to establish equivalent safety with the reference product.

I have also developed several mRNA vaccines, including COVID-19, flu, HPV, HIV, and tuberculosis, that are under advanced stages of development across the globe, including one with a biosimilar status. Today, the world needs about 8 billion doses of COVID-19 vaccines that work. I have concluded that we can make 1 billion doses using 30 L bioreactors in 6 months with our cost of goods not exceeding $0.50 per dose in bulk and $0.90 in final packaging if the vaccine is manufactured in the United States; the costs can be lower if manufactured in developing countries. For example, the cost of Moderna single dose is $32 to $37, and Pfizer’s, $22 in final packaging. I can confirm these costs of manufacturing that make the commercial manufacturing of COVID-19 vaccines a highly profitable project.

While there is an excess of COVID-19 vaccine in the United States, the rest of the world is still starving for it. The WHO has also told me that the world needs 8 billion doses of COVID-19 vaccines and that they will be very proactive if anyone can supply the mRNA vaccines; the trust in all other vaccines has declined. This is a remarkable business opportunity for many companies since the capital expenditures (CAPEX) and operating expenditures (OPEX) are very small. In my next article on the topic, I will provide details of strategies to take the mRNA vaccines to market fast and reduce CAPEX and OPEX significantly. I want to enable newcomers to appreciate that mRNA technology will revolutionize health care, and there are many opportunities to join this revolution.

Summary

mRNA vaccines are chemically derived and have fixed chemical structures; it is possible to fully replicate a reference product sequence, reducing the burden of proving biosimilarity required for therapeutic proteins. The FDA has already suggested a new pathway for mRNA vaccines, but this path will only come into being when enough companies join in taking steps toward this strategy.

Watch for the second article in this series: Biosimilar mRNA Vaccines—Fast-to-Market Strategies.

Adblock test (Why?)



Source link

Continue Reading

Health

Majority of COVID-19 cases at large public events were among vaccinated Americans: CDC study – CTV News

Published

 on


A new study by the U.S. Centers for Disease Control and Prevention showed that three-quarters of individuals who became infected with COVID-19 at public events in a Massachusetts county had been fully vaccinated.

The study, published on Friday, showed that three-quarters of those infected were fully vaccinated, suggesting the Delta variant of the virus is highly contagious.

A separate CDC internal document, first reported by the Washington Post on Friday, described the Delta variant as being as transmissible as chickenpox and cautioned it could cause severe disease.

The new study’s authors recommended that local health authorities consider requiring masks in indoor public settings regardless of vaccination status or the number of coronavirus cases in the community.

The study identified 469 people with COVID-19, 74% of whom were fully vaccinated, following large public events in the state’s Barnstable County. Testing identified the Delta variant in 90% of virus specimens from 133 people.

The viral load was similar in people who were fully vaccinated and those who were unvaccinated, the CDC said.

High viral loads suggest an increased risk of transmission and raised concern that, unlike with other variants, vaccinated people infected with Delta can transmit the virus, it said.

The finding of the report “is concerning and was a pivotal discovery leading to CDC’s updated mask recommendation,” CDC director Rochelle Walensky said in a statement.

On Tuesday, the CDC reversed course on guidance for mask wearing, calling for their use in areas where cases are surging as a precaution against the possible transmission of the virus by fully vaccinated people.

“The masking recommendation was updated to ensure the vaccinated public would not unknowingly transmit virus to others, including their unvaccinated or immunocompromised loved ones,” Walensky said in a statement.

Reporting by Manas Mishra in Bengaluru; Editing by Howard Goller

Adblock test (Why?)



Source link

Continue Reading

Health

Obstetrician groups recommend COVID vaccine during pregnancy – Burnaby Now

Published

 on


Two leading obstetricians’ groups on Friday recommended COVID-19 shots for all pregnant women, citing concerns over rising cases and low vaccination rates.

The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine said vaccinations in tens of thousands of pregnant women over the past several months have shown the shots are safe and effective during pregnancy.

COVID-19 during pregnancy increases risks for severe complications and can also increase chances for preterm birth. U.S. government data show only about 16% of pregnant women have received one or more doses of the COVID-19 vaccine.

The two groups had previously said pregnant people shouldn’t be excluded from vaccination but stopped short of endorsing the shots.

The president of the OB-GYN group, Dr. Martin Tucker, said in a statement that doctors should enthusiastically recommend the shots to their patients.

Dr. Emily Miller, obstetrics chief at Northwestern Medicine in Chicago, said she hopes the new recommendation “will help pregnant people feel more confident in their decision to get the COVID-19 vaccine as soon as possible.”

Miller is a member of the maternal-fetal medicine group’s COVID-19 task force.

Pregnant women weren’t included in studies that led to emergency authorization of the vaccines. Experts including the federal Centers for Disease Control and Prevention have not discouraged vaccination during pregnancy and have said available safety information is reassuring.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

The Associated Press

Adblock test (Why?)



Source link

Continue Reading

Trending